References
- Hartmann O, Le Corroller A G, Blaise D, Michon J, Philip I, Norol F, et al. Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. A randomized, controlled trial. Ann Intern Med 1997; 126: 600–607
- Petit I, Szyper-Kravitz M, Nagler A, Lahav M, Peled A, Habler L, et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 2002; 3: 687–694
- Narayanasami U, Kanteti R, Morelli J, Klekar A, Al-Olama A, Keating C, et al. Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood 2001; 98: 2059–2064
- Stewart D A, Guo D, Morris D, Poon M C, Ruether B A, Jones A R, et al. Superior autologous blood stem cell mobilization from dose-intensive cyclophosphamide, etoposide, cisplatin plus G-CSF than from less intensive chemotherapy regimens. Bone Marrow Transplant 1999; 23: 111–117
- Demirer T, Ayli M, Ozcan M, Gunel N, Haznedar R, Dagli M, et al. Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte colony-stimulating factor (rhG-CSF): a randomized evaluation of different doses of rhG-CSF. Br J Haematol 2002; 116: 468–474
- Bolwell B J, Pohlman B, Rybicki L, Sobecks R, Dean R, Curtis J, et al. Patients mobilizing large numbers of CD34+ cells (‘super mobilizers’) have improved survival in autologous stem cell transplantation for lymphoid malignancies. Bone Marrow Transplant, in press
- Milone G, Leotta S, Battiato K, Murgano P, Mercurio S, Strano A, et al. Intermediate dose etoposide plus G-CSF 16 mcg/kg is more effective than cyclophosphamide 4 gr/m2 plus G-CSF 10 mcg/kg in PBSC mobilization of lymphoma patients. Leuk Lymphoma 2007; 48: 1950–1960
- Kanfer E J, McGuigan D, Samson D, Abboudi Z, Abrahamson G, Apperley J F, et al. High-dose etoposide with granulocyte colony-stimulating factor for mobilization of peripheral blood progenitor cells: efficacy and toxicity at three dose levels. Br J Cancer 1998; 78: 928–932
- Copelan E, Hoshaw-Woodard S, Elder P, Penza S, Farag S, Marcucci G, et al. Therapy-related myelodysplasia and leukemia occur infrequently following VP-16 priming and autotransplantation without total body irradiation. Bone Marrow Transplant 2004; 34: 85–87